Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H2 2018
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H2 2018
SUMMARY
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Alpha-galactosidase is a glycoside hydrolase enzyme encoded by the GLA gene. This enzyme is a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. It predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose. Mutations in this gene affect the synthesis and stability of this enzyme which causes Fabry's disease.
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 7 respectively. Similarly, the universities portfolio in Unknown stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders which include indications Fabry Disease.
The latest report Alpha Galactosidase A - Pipeline Review, H2 2018, outlays comprehensive information on the Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Alpha-galactosidase is a glycoside hydrolase enzyme encoded by the GLA gene. This enzyme is a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. It predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose. Mutations in this gene affect the synthesis and stability of this enzyme which causes Fabry's disease.
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 7 respectively. Similarly, the universities portfolio in Unknown stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders which include indications Fabry Disease.
The latest report Alpha Galactosidase A - Pipeline Review, H2 2018, outlays comprehensive information on the Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22)
- The report reviews Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Overview
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Companies Involved in Therapeutics Development
Amicus Therapeutics Inc
Avrobio Inc
Biosidus SA
Chiesi Farmaceutici SpA
greenovation Biotech GmbH
iBio Inc
Moderna Therapeutics Inc
Pharming Group NV
Sangamo Therapeutics Inc
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Drug Profiles
(ATB-101 + migalastat hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
agalsidase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
agalsidase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
agalsidase beta biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVRRD-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Alpha Galactosidase A for Fabry Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate GLA for Fabry Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
migalastat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOSS-AGAL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mRNA-3630 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegunigalsidase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-920 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Dormant Products
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Discontinued Products
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2018: AVROBIO announces updated clinical data for AVR-RD-01 gene therapy in fabry disease
Sep 21, 2018: Protalix BioTherapeutics reports positive preliminary data from the BRIDGE Study of pegunigalsidase alfa for the treatment of Fabry Disease
Sep 17, 2018: Protalix BioTherapeutics to present preliminary data from the BRIDGE Study of pegunigalsidase alfa for the treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018
Aug 10, 2018: FDA approves Galafold (migalastat) for the treatment of certain adult patients with Fabry Disease
May 30, 2018: Amicus Therapeutics Launches Galafold (Migalastat) for Fabry Disease in Japan
May 25, 2018: Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress
Mar 22, 2018: Amicus Therapeutics Announces Approval of Galafold (Migalastat) for Fabry Disease in Japan
Feb 12, 2018: U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
Jan 31, 2018: Protalix BioTherapeutics' pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration
Jan 29, 2018: Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold (migalastat) for Fabry Disease in Canada
Jan 29, 2018: Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium 2018
Jan 17, 2018: Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in Spain
Dec 27, 2017: Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
Dec 20, 2017: Greenovation Biotech Reports Positive Clinical Data from the Phase 1 Safety Study for moss-aGal
Dec 14, 2017: Amicus Therapeutics Submits New Drug Application to U.S. FDA for Migalastat for Treatment of Fabry Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Overview
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Companies Involved in Therapeutics Development
Amicus Therapeutics Inc
Avrobio Inc
Biosidus SA
Chiesi Farmaceutici SpA
greenovation Biotech GmbH
iBio Inc
Moderna Therapeutics Inc
Pharming Group NV
Sangamo Therapeutics Inc
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Drug Profiles
(ATB-101 + migalastat hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
agalsidase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
agalsidase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
agalsidase beta biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVRRD-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Alpha Galactosidase A for Fabry Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate GLA for Fabry Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
migalastat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOSS-AGAL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mRNA-3630 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegunigalsidase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-920 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Dormant Products
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Discontinued Products
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2018: AVROBIO announces updated clinical data for AVR-RD-01 gene therapy in fabry disease
Sep 21, 2018: Protalix BioTherapeutics reports positive preliminary data from the BRIDGE Study of pegunigalsidase alfa for the treatment of Fabry Disease
Sep 17, 2018: Protalix BioTherapeutics to present preliminary data from the BRIDGE Study of pegunigalsidase alfa for the treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018
Aug 10, 2018: FDA approves Galafold (migalastat) for the treatment of certain adult patients with Fabry Disease
May 30, 2018: Amicus Therapeutics Launches Galafold (Migalastat) for Fabry Disease in Japan
May 25, 2018: Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress
Mar 22, 2018: Amicus Therapeutics Announces Approval of Galafold (Migalastat) for Fabry Disease in Japan
Feb 12, 2018: U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
Jan 31, 2018: Protalix BioTherapeutics' pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration
Jan 29, 2018: Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold (migalastat) for Fabry Disease in Canada
Jan 29, 2018: Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium 2018
Jan 17, 2018: Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in Spain
Dec 27, 2017: Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
Dec 20, 2017: Greenovation Biotech Reports Positive Clinical Data from the Phase 1 Safety Study for moss-aGal
Dec 14, 2017: Amicus Therapeutics Submits New Drug Application to U.S. FDA for Migalastat for Treatment of Fabry Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Amicus Therapeutics Inc, H2 2018
Pipeline by Avrobio Inc, H2 2018
Pipeline by Biosidus SA, H2 2018
Pipeline by Chiesi Farmaceutici SpA, H2 2018
Pipeline by greenovation Biotech GmbH, H2 2018
Pipeline by iBio Inc, H2 2018
Pipeline by Moderna Therapeutics Inc, H2 2018
Pipeline by Pharming Group NV, H2 2018
Pipeline by Sangamo Therapeutics Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Amicus Therapeutics Inc, H2 2018
Pipeline by Avrobio Inc, H2 2018
Pipeline by Biosidus SA, H2 2018
Pipeline by Chiesi Farmaceutici SpA, H2 2018
Pipeline by greenovation Biotech GmbH, H2 2018
Pipeline by iBio Inc, H2 2018
Pipeline by Moderna Therapeutics Inc, H2 2018
Pipeline by Pharming Group NV, H2 2018
Pipeline by Sangamo Therapeutics Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Amicus Therapeutics Inc
Avrobio Inc
Biosidus SA
Chiesi Farmaceutici SpA
greenovation Biotech GmbH
iBio Inc
Moderna Therapeutics Inc
Pharming Group NV
Sangamo Therapeutics Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Amicus Therapeutics Inc
Avrobio Inc
Biosidus SA
Chiesi Farmaceutici SpA
greenovation Biotech GmbH
iBio Inc
Moderna Therapeutics Inc
Pharming Group NV
Sangamo Therapeutics Inc
